SK Capital Partners in discussions to create an integrated global API CDMO leader

The private investment firm plans to acquire SEQENS and merge it with Wavelength Pharmaceuticals

The company also plans to merge one of its portfolio companies, Wavelength Pharmaceuticals, to create a global leader in the API & CDMO sectors.

Both elements of the deal are expected to complete by the end of 2021.

SEQENS is headquartered in France, and through its 3000 employees in 19 production sites and seven R&D centers around the world, generates an annual turnover of over €1 billion.

The company focuses on critical consumer care analgesic APIs, offering a broad portfolio of generic APIs and intermediates, as well as custom development and manufacturing services across a wide range of pharmaceutical technologies.

Wavelength Pharmaceuticals, a developer and manufacturer of APIs, produces more than 630 metric tons of commercial products every year and offers a full range of API CDMO services from preclinical grams to multi-ton commercial scale.

The proposed merger will create a scaled leader of global industrial footprint and further extend both companies’ broad portfolio of products, services and advanced pharmaceutical technologies; it could also increase the group’s industrial footprint, its product and technology portfolio.